Genomic characterization of high-risk non-muscle invasive bladder cancer
| Autor: | Francis J. Giles, Joshua J. Meeks, Nike Beaubier, Daniel T. Oberlin, Alfred Rademaker, Sachin Gopalkrishna Pai, Julia A. Elvin, Kyle Fedorchak, Sohail Balasubramanian, Benedito A. Carneiro |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Risk Oncology medicine.medical_specialty Pathology medicine.medical_treatment 030232 urology & nephrology 03 medical and health sciences 0302 clinical medicine CDKN2A Internal medicine medicine Humans Genetic Predisposition to Disease Neoplasm Invasiveness Aged Neoplasm Staging Preventive healthcare Aged 80 and over mutation burden Hematology Bladder cancer business.industry Carcinoma in situ Cancer Genomics Immunotherapy Middle Aged invasion medicine.disease Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Mutation Disease Progression bladder cancer Biomarker (medicine) Female progression business Biomarkers Research Paper Follow-Up Studies |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Joshua J. Meeks 1, * , Benedito A. Carneiro 2, * , Sachin G. Pai 2 , Daniel T. Oberlin 1 , Alfred Rademaker 4 , Kyle Fedorchak 5 , Sohail Balasubramanian 5 , Julia Elvin 5 , Nike Beaubier 3 , Francis J. Giles 2 1 Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 2 Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA 3 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 4 Northwestern University Department of Preventive Medicine, Chicago, IL, USA 5 Foundation Medicine Inc, Cambridge, MA, USA * These authors contributed equally to this work Correspondence to: Joshua J. Meeks, email: joshua.meeks@northwestern.edu Benedito A. Carneiro, email: benedito.carneiro@northwestern.edu Keywords: bladder cancer, mutation burden, progression, invasion Received: August 29, 2016 Accepted: October 05, 2016 Published: October 14, 2016 ABSTRACT The genetic mechanisms associated with progression of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have not been described. We conducted selective next-generation sequencing (NGS) of HR-NMIBC and compared the genomic profiles of cancers that responded to intravesical therapy and those that progressed to muscle-invasive or advanced disease. DNA was extracted from paraffin-embedded sections from 25 HR-NMIBCs (22 with T1HG; 3 with TaHG with or without carcinoma in situ ). Ten patients with HR-NMIBC developed progression (pT2+ or N+) (“progressors”). Fifteen patients had no progression (“non-progressors”). Tissue from 11 patients with metastatic bladder cancer (BC) were analyzed for comparison. We found no difference in frequency of mutations of TP53 , PIK3CA , or KMT2D between the primary tumors of progressors compared to non-progressors and metastatic tumors. An increased frequency of deletions of CDKN2A/B was identified in tumors at progression (37%) compared to non-progressors (6%) ( p = 0.10). We found a significant decrease in total mutational burden (TMB) that has been associated with immunotherapy response comparing non-progressors, progressors and metastatic tumors at 15, 10.1 and 5.1 mutations/MB respectively ( p = 0.02). This association suggests more advanced tumors have decreased neoantigen burden and may explain the mechanism of BCG response in non-progressors. We found no novel genetic drivers in progressors and HR-NMIBC had many genetic features similar to metastatic BC. Loss of CDKN2A/B may occur late during invasion of BC and may represent an important step in progression. Further research is necessary to evaluate TMB and loss of CDKN2A/B locus as a biomarker for progression of NMIBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|